New drug duo targets tough lung cancer mutation

NCT ID NCT07227025

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study tests a combination of two drugs, amivantamab and olomorasib, in people with a specific type of advanced lung cancer (KRAS G12C mutant NSCLC) that has spread. The goal is to find the safest and most effective dose and see if the combo can shrink tumors or slow their growth. About 60 participants will be enrolled, and the study is currently recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ankara Bilkent Sehir Hastanesi

    RECRUITING

    Çankaya, 06800, Turkey (Türkiye)

  • Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi

    RECRUITING

    Ankara, 06620, Turkey (Türkiye)

  • Asan Medical Center

    RECRUITING

    Seoul, 05505, South Korea

  • Harbin medical university cancer hospital

    RECRUITING

    Harbin, 150000, China

  • Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi

    RECRUITING

    Istanbul, 34010, Turkey (Türkiye)

  • New York University Langone Medical Center

    RECRUITING

    New York, New York, 10016, United States

  • Oncology Consultants Cancer Center

    SUSPENDED

    Houston, Texas, 77030, United States

  • Princess Margaret Hospital

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Samsung Medical Center

    RECRUITING

    Seoul, 06351, South Korea

  • Severance Hospital Yonsei University Health System

    RECRUITING

    Seoul, 03722, South Korea

  • Shanghai East Hospital

    RECRUITING

    Shanghai, 310000, China

  • The First Affiliated Hospital Sun Yat sen University

    RECRUITING

    Guangzhou, 510060, China

  • Virginia Cancer Specialists

    RECRUITING

    Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.